{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:36:31Z","timestamp":1793370991390,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaad.2025.05.1455","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:10:17Z","timestamp":1749813017000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["RASopathies. Part I: Genetics and therapeutic considerations"],"prefix":"10.1016","author":[{"given":"Zachary J.","family":"Jaeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Maverakis Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley D.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl W.","family":"Staser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.05.1455_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6297","key":"10.1016\/j.jaad.2025.05.1455_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/348125a0","article-title":"The GTPase superfamily: a conserved switch for diverse cell functions","volume":"348","author":"Bourne","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2025.05.1455_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.bi.62.070193.004223","article-title":"Function and regulation of ras","volume":"62","author":"Lowy","year":"1993","journal-title":"Annu Rev Biochem"},{"issue":"Pt 5","key":"10.1016\/j.jaad.2025.05.1455_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1242\/jcs.01660","article-title":"The Ras superfamily at a glance","volume":"118","author":"Wennerberg","year":"2005","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jmedgenet-2011-100637","article-title":"Keratinocytic epidermal nevi are associated with mosaic RAS mutations","volume":"49","author":"Hafner","year":"2012","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4161\/cc.23108","article-title":"Mosaic RASopathies","volume":"12","author":"Hafner","year":"2013","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.jaad.2025.05.1455_bib8","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1101\/gad.190876.112","article-title":"A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1","volume":"26","author":"Stowe","year":"2012","journal-title":"Genes Dev"},{"issue":"27","key":"10.1016\/j.jaad.2025.05.1455_bib9","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1073\/pnas.1607298113","article-title":"The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation","volume":"113","author":"Dunzendorfer-Matt","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"R2","key":"10.1016\/j.jaad.2025.05.1455_bib10","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1093\/hmg\/ddw191","article-title":"Pathogenetics of the RASopathies","volume":"25","author":"Tidyman","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1455_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.bbamcr.2007.01.012","article-title":"Ras oncogenes and their downstream targets","volume":"1773","author":"Rajalingam","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib12","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3892\/ol.2016.5110","article-title":"The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC","volume":"12","author":"Li","year":"2016","journal-title":"Oncol Lett"},{"issue":"22","key":"10.1016\/j.jaad.2025.05.1455_bib13","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"issue":"14","key":"10.1016\/j.jaad.2025.05.1455_bib15","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"issue":"9863","key":"10.1016\/j.jaad.2025.05.1455_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1455_bib17","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.ajhg.2021.09.007","article-title":"SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype","volume":"108","author":"Motta","year":"2021","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/340847","article-title":"PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity","volume":"70","author":"Tartaglia","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/adc.2006.104547","article-title":"The natural history of Noonan syndrome: a long-term follow-up study","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jmg.24.1.9","article-title":"Noonan syndrome","volume":"24","author":"Allanson","year":"1987","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000342251","article-title":"LEOPARD syndrome: clinical features and gene mutations","volume":"3","author":"Martinez-Quintana","year":"2012","journal-title":"Mol Syndromol"},{"issue":"10","key":"10.1016\/j.jaad.2025.05.1455_bib22","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","article-title":"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects","volume":"281","author":"Kontaridis","year":"2006","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib23","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049107","article-title":"The RASopathies: from pathogenetics to therapeutics","volume":"15","author":"Hebron","year":"2022","journal-title":"Dis Model Mech"},{"issue":"20","key":"10.1016\/j.jaad.2025.05.1455_bib24","first-page":"354","article-title":"The neurofibromatoses","volume":"117","author":"Farschtschi","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.36793","article-title":"Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues","volume":"167A","author":"Rauen","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ajmg.1320210307","article-title":"Noonan phenotype associated with neurofibromatosis","volume":"21","author":"Allanson","year":"1985","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0004.1996.tb04328.x","article-title":"Neurofibromatosis\/Noonan phenotype: a variable feature of type 1 neurofibromatosis","volume":"49","author":"Colley","year":"1996","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib28","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ajmg.a.33996","article-title":"Lethal presentation of neurofibromatosis and Noonan syndrome","volume":"155A","author":"Prada","year":"2011","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.20023","article-title":"Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS)","volume":"119A","author":"Baralle","year":"2003","journal-title":"Am J Med Genet A"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1455_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/hmg\/1.9.735","article-title":"Analysis of mutations at the neurofibromatosis 1 (NF1) locus","volume":"1","author":"Upadhyaya","year":"1992","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaad.2025.05.1455_bib31","series-title":"GeneReviews((R))","article-title":"Legius syndrome","author":"Legius","year":"2010"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib32","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/379793","article-title":"Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations","volume":"73","author":"Eerola","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1455_bib33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/CIRCULATIONAHA.116.026886","article-title":"Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling","volume":"136","author":"Amyere","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1455_bib34","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/humu.22431","article-title":"RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation","volume":"34","author":"Revencu","year":"2013","journal-title":"Hum Mutat"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1455_bib35","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/humu.20746","article-title":"Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations","volume":"29","author":"Revencu","year":"2008","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jmedgenet-2019-106024","article-title":"RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation","volume":"57","author":"Revencu","year":"2020","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.jaad.2025.05.1455_bib37","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/ng1641","article-title":"Germline mutations in HRAS proto-oncogene cause Costello syndrome","volume":"37","author":"Aoki","year":"2005","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.31047","article-title":"HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation","volume":"140","author":"Gripp","year":"2006","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jmg.2005.040352","article-title":"Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases","volume":"43","author":"Kerr","year":"2006","journal-title":"J Med Genet"},{"issue":"20","key":"10.1016\/j.jaad.2025.05.1455_bib40","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/ajmg.a.31456","article-title":"Somatic mosaicism for an HRAS mutation causes Costello syndrome","volume":"140","author":"Gripp","year":"2006","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jaad.2025.05.1455_bib41","series-title":"GeneReviews((R))","article-title":"HRAS-related Costello syndrome","author":"Gripp","year":"2006"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-3476(98)70284-7","article-title":"Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause","volume":"133","author":"Johnson","year":"1998","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/MOP.0b013e3282f161dc","article-title":"Costello syndrome and related disorders","volume":"19","author":"Quezada","year":"2007","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/ajmg.a.35292","article-title":"Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey","volume":"158A","author":"Abe","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"50","key":"10.1016\/j.jaad.2025.05.1455_bib45","doi-asserted-by":"crossref","first-page":"20152","DOI":"10.1073\/pnas.1311381110","article-title":"Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline","volume":"110","author":"Giannoulatou","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1455_bib46","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1002\/ajmg.a.33687","article-title":"Costello syndrome with severe cutis laxa and mosaic HRAS G12S mutation","volume":"152A","author":"Girisha","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajmg.a.32639","article-title":"Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism","volume":"149A","author":"Sol-Church","year":"2009","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0092-8674(89)90427-3","article-title":"Expression of the H-ras proto-oncogene is controlled by alternative splicing","volume":"58","author":"Cohen","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2025.05.1455_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12881-015-0184-z","article-title":"The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model","volume":"16","author":"Garcia-Cruz","year":"2015","journal-title":"BMC Med Genet"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006039","article-title":"The splicing efficiency of activating HRAS mutations can determine Costello syndrome phenotype and frequency in cancer","volume":"12","author":"Hartung","year":"2016","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1523\/JNEUROSCI.1547-15.2016","article-title":"Human iPS cell-derived neurons uncover the impact of increased Ras signaling in Costello syndrome","volume":"36","author":"Rooney","year":"2016","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ng1749","article-title":"Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome","volume":"38","author":"Niihori","year":"2006","journal-title":"Nat Genet"},{"issue":"5765","key":"10.1016\/j.jaad.2025.05.1455_bib53","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1126\/science.1124642","article-title":"Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome","volume":"311","author":"Rodriguez-Viciana","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ced.12209","article-title":"Naevus sebaceus: a mosaic RASopathy","volume":"39","author":"Aslam","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1455_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.2316","article-title":"Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome","volume":"44","author":"Groesser","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1468-3083.2002.00543.x","article-title":"Sebaceus naevi: a clinicopathologic study","volume":"16","author":"Munoz-Perez","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.05.1455_bib57","series-title":"Neurocutaneous disorders: a clinical, diagnostic and therapeutic approach","first-page":"143","article-title":"Epidermal nevus syndromes","author":"Waul","year":"2022"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1455_bib58","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/jid.2013.70","article-title":"Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS","volume":"133","author":"Kinsler","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2133.1981.tb00954.x","article-title":"Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies","volume":"104","author":"Castilla","year":"1981","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib60","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jaad.2008.11.022","article-title":"Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center's experience","volume":"61","author":"Lovett","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0190-9622(96)90674-X","article-title":"Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis","volume":"35","author":"DeDavid","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30859","article-title":"Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: a rare but fatal condition","volume":"71","author":"Abele","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1455_bib63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/bjc.2017.49","article-title":"MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children","volume":"116","author":"Kinsler","year":"2017","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1455_bib64","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2013.24","article-title":"Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell","volume":"133","author":"Groesser","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.05.1455_bib65","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/jid.2014.195","article-title":"Next-generation sequencing of nevus spilus-type congenital melanocytic nevus: exquisite genotype-phenotype correlation in mosaic RASopathies","volume":"134","author":"Kinsler","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib66","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/jid.2014.6","article-title":"Activating HRAS mutation in nevus spilus","volume":"134","author":"Sarin","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib67","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jaad.2020.12.082","article-title":"Phacomatosis spilosebacea: a new name for a distinctive binary genodermatosis","volume":"89","author":"Torchia","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1455_bib68","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jdcr.2019.07.031","article-title":"Phacomatosis pigmentokeratotica without extracutaneous abnormalities: 12-year follow-up","volume":"5","author":"Hannah","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/pde.13119","article-title":"Phacomatosis pigmentokeratotica: a mosaic RASopathy with malignant potential","volume":"34","author":"Om","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29639","article-title":"Cutaneous mosaic RASopathies associated with rhabdomyosarcoma","volume":"69","author":"Davies","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"2 Pt 2","key":"10.1016\/j.jaad.2025.05.1455_bib71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0190-9622(98)70381-0","article-title":"Familial multiple blue nevi","volume":"39","author":"Knoell","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"7229","key":"10.1016\/j.jaad.2025.05.1455_bib72","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"issue":"5141","key":"10.1016\/j.jaad.2025.05.1455_bib73","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.8266082","article-title":"Separate GTP binding and GTPase activating domains of a G alpha subunit","volume":"262","author":"Markby","year":"1993","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.jaad.2025.05.1455_bib74","doi-asserted-by":"crossref","first-page":"28086","DOI":"10.18632\/oncotarget.8578","article-title":"Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway","volume":"7","author":"Perez-Alea","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.jaad.2025.05.1455_bib75","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1455_bib76","first-page":"235","article-title":"Activating mutation of GS alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes","volume":"52","author":"Kim","year":"1999","journal-title":"Horm Res"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib77","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/JME-13-0297","article-title":"Three intragenic suppressors of a GTPase-deficient allele of GNAS associated with McCune-Albright syndrome","volume":"52","author":"Turcic","year":"2014","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.jaad.2025.05.1455_bib78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1172-3-12","article-title":"McCune-Albright syndrome","volume":"3","author":"Dumitrescu","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaad.2025.05.1455_bib79","series-title":"GeneReviews((R))","article-title":"Encephalocraniocutaneous lipomatosis","author":"Moog","year":"2022"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib80","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/cge.12775","article-title":"Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal syndrome and encephalocraniocutaneous lipomatosis","volume":"90","author":"Boppudi","year":"2016","journal-title":"Clin Genet"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1455_bib81","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/jmedgenet-2019-106732","article-title":"Detecting mosaic variants in patients with somatic overgrowth syndromes using cell-free circulating DNA and deep sequencing","volume":"57","author":"Shen","year":"2020","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib82","first-page":"275","article-title":"The utility of liquid biopsy in clinical genetic diagnosis of cancer and monogenic mosaic disorders","volume":"35","author":"Hallermayr","year":"2023","journal-title":"Med Genet"},{"key":"10.1016\/j.jaad.2025.05.1455_bib83","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jid.2024.04.031","article-title":"RNA therapy for oncogenic NRAS-driven nevi induces apoptosis","volume":"145","author":"Bryant","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/jhg.2015.114","article-title":"Recent advances in RASopathies","volume":"61","author":"Aoki","year":"2016","journal-title":"J Hum Genet"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajmg.c.32024","article-title":"New prospectives on treatment opportunities in RASopathies","volume":"190","author":"Gelb","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib86","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ajmg.c.30294","article-title":"Costello and cardio-facio-cutaneous syndromes: moving toward clinical trials in RASopathies","volume":"157C","author":"Rauen","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1455_bib87","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155888","article-title":"Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition","volume":"8","author":"Sheppard","year":"2023","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.jaad.2025.05.1455_bib88","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.jaad.2025.05.1455_bib89","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1073\/pnas.1904529116","article-title":"Drugging an undruggable pocket on KRAS","volume":"116","author":"Kessler","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.jaad.2025.05.1455_bib90","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib91","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/CCO.0000000000000711","article-title":"MEK inhibitors in RASopathies","volume":"33","author":"Bergqvist","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"17","key":"10.1016\/j.jaad.2025.05.1455_bib92","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib93","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2025.05.1455_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1001105","article-title":"Case report: progressive central conducting lymphatic abnormalities in the RASopathies. Two case reports, including successful treatment by MEK inhibition","volume":"13","author":"Gordon","year":"2022","journal-title":"Front Genet"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1455_bib95","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/genes13091503","article-title":"Severe lymphatic disorder and multifocal atrial tachycardia treated with trametinib in a patient with Noonan syndrome and SOS1 mutation","volume":"13","author":"Lioncino","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jaad.2025.05.1455_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib97","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamadermatol.2018.4653","article-title":"Genotype-guided medical treatment of an arteriovenous malformation in a child","volume":"155","author":"Lekwuttikarn","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2025.05.1455_bib98","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.3390\/ijms22169037","article-title":"Arteriovenous malformations-current understanding of the pathogenesis with implications for treatment","volume":"22","author":"Schimmel","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib99","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ajhg.2017.01.018","article-title":"Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation","volume":"100","author":"Couto","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib100","first-page":"141","article-title":"MEK inhibitors for the treatment of extracranial arteriovenous malformations","volume":"5","author":"Xu","year":"2023","journal-title":"Chi J Plast Recon Surg"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1455_bib101","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MPH.0000000000001170","article-title":"Encephalocraniocutaneous lipomatosis","volume":"40","author":"Bavle","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib102","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers","volume":"28","author":"Peng","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib103","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1455_bib104","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","article-title":"Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study","volume":"84","author":"Boull","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1455_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.05.043","article-title":"LB949 development of topical MEK inhibitor, NFX-179, as a chemopreventive agent for squamous cell carcinoma","volume":"140","author":"Shah","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"18","key":"10.1016\/j.jaad.2025.05.1455_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk4946","article-title":"Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1","volume":"10","author":"Sarin","year":"2024","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib109","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/pde.15523","article-title":"Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning-Feuerstein-Mims syndrome","volume":"41","author":"Haller","year":"2024","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2009-09-242875","article-title":"Mast cells and the neurofibroma microenvironment","volume":"116","author":"Staser","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib111","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12307-012-0115-x","article-title":"The plexiform neurofibroma microenvironment","volume":"5","author":"Yang","year":"2012","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.jaad.2025.05.1455_bib112","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-pathol-011811-132441","article-title":"Pathogenesis of plexiform neurofibroma: tumor-stromal\/hematopoietic interactions in tumor progression","volume":"7","author":"Staser","year":"2012","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MOH.0b013e328339511b","article-title":"Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells","volume":"17","author":"Staser","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib114","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.4049\/jimmunol.178.4.2527","article-title":"K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+\/- mast cells","volume":"178","author":"Khalaf","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/-- and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib116","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/pbc.25763","article-title":"Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas","volume":"63","author":"Ferguson","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"10.1016\/j.jaad.2025.05.1455_bib117","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90220","article-title":"Low-dose dasatinib rescues cardiac function in Noonan syndrome","volume":"1","author":"Yi","year":"2016","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib118","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10557-021-07169-z","article-title":"Low-dose dasatinib ameliorates hypertrophic cardiomyopathy in Noonan syndrome with multiple lentigines","volume":"36","author":"Yi","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ejh.12052","article-title":"Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization","volume":"90","author":"Drucker","year":"2013","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib120","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1172\/JCI46399","article-title":"RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it","volume":"121","author":"Gelb","year":"2011","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib121","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ajmg.a.36982","article-title":"Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog","volume":"167A","author":"Hahn","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib122","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI44972","article-title":"Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation","volume":"121","author":"Marin","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1455_bib123","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1455_bib124","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/1078-0432.CCR-14-3214","article-title":"Targeting RAS membrane association: back to the future for anti-RAS drug discovery?","volume":"21","author":"Cox","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1455_bib125","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10555-020-09902-w","article-title":"K-Ras prenylation as a potential anticancer target","volume":"39","author":"Baranyi","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1455_bib126","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s12253-019-00789-9","article-title":"Next generation lipophilic bisphosphonate shows antitumor effect in colorectal cancer in vitro and in vivo","volume":"26","author":"Baranyi","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1455_bib127","doi-asserted-by":"crossref","first-page":"11952","DOI":"10.1038\/s41598-020-68615-w","article-title":"N-myristoyltransferase-1 is necessary for lysosomal degradation and mTORC1 activation in cancer cells","volume":"10","author":"Chen","year":"2020","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1455_bib128","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.jid.2024.06.1259","article-title":"LB1002 N-Myristoyltransferase: a potential target in melanoma","volume":"144","author":"Maverakis Ramirez","year":"2024","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225023394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225023394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:25:45Z","timestamp":1793370345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225023394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":127,"alternative-id":["S0190962225023394"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1455","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RASopathies. Part I: Genetics and therapeutic considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.106","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}